The efficacy of salmeterol/fluticasone inhalation on systemic inflammatory markers in patients with chronic obstructive pulmonary diseases

The efficacy of salmeterol/fluticasone inhalation on systemic inflammatory markers in patients with chronic obstructive pulmonary diseases - SFC effects on the systemic inflammatory markers in COPD patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008102

Enrollment

Registered

2012-06-05

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary diseases

Interventions

salmeterol inhalation salmeterol/fluticasone inhalation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: able to read and sign the letter of consent be diagnosed as COPD has FEV1/FVC <70% has no other disease cause of the obstruction except COPD with smoking status more than 10 pack years able to inhale the discus inhalation medicine able to fill in the CAT(COPD assessment test)

Exclusion criteria

Exclusion criteria: have any of tuberculosis or acute airway infections associated with bronchial asthma had COPD exacerbation in 4 weeks with pregnacy, lactating with any of severe heart disease, liver disease, renal disease, hematological disease or infection disease who the doctor in charge judge as to be excepted

Design outcomes

Primary

Measure	Time frame
The changes of PARK/CCL-18, CC-16, serum arginase, and urinary beta isoprostane	—

Secondary

Measure	Time frame
The changes of lung function	—

Countries

Japan

Contacts

Public ContactYasushi Obase

Kawasaki Medical School Respiratory diseases

obaseya@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026